NSCLC: Anti-PD-L1 immunotherapy breaks ground, buys time for some
www.pulmccm.org
Immunotherapy -- creating antibodies to tumor markers, then activating the immune system to selectively kill cancer cells -- is the newest and most-hyped frontier of oncology. And with some justification: the mechanism is cleaner and kinder than chemotherapy, and being a whole new treatment modality, can complement and augment traditional therapies.
NSCLC: Anti-PD-L1 immunotherapy breaks ground, buys time for some
NSCLC: Anti-PD-L1 immunotherapy breaks…
NSCLC: Anti-PD-L1 immunotherapy breaks ground, buys time for some
Immunotherapy -- creating antibodies to tumor markers, then activating the immune system to selectively kill cancer cells -- is the newest and most-hyped frontier of oncology. And with some justification: the mechanism is cleaner and kinder than chemotherapy, and being a whole new treatment modality, can complement and augment traditional therapies.